Merck & Co., Inc. Equity Securities, FV-NI, Unrealized Gain (Loss)
Merck & Co., Inc. (MRK) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of -$41.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-07
- Merck & Co., Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was -$41.00M, a 127.89% decline year-over-year.
- Merck & Co., Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $126.00M.
- Merck & Co., Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was -$156.00M.
- Merck & Co., Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $367.00M.
- Merck & Co., Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $474.00M.
- Merck & Co., Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$30.00M, a 107.30% decline from fiscal 2023.
- Merck & Co., Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $411.00M.
- Merck & Co., Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$462.00M.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$41.00M 10-Q · filed 2026-08-07 | $86.00M 10-Q · filed 2026-08-07 | -$71.00M derived: sum of 3 quarters · filed 2026-08-07 | $296.00M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $126.00M 10-Q · filed 2026-05-04 | -$30.00M derived: sum of 2 quarters · filed 2026-05-04 | $337.00M derived: sum of 3 quarters · filed 2026-05-04 | $484.00M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | -$156.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $211.00M derived: sum of 2 quarters · filed 2026-02-24 | $358.00M derived: sum of 3 quarters · filed 2026-08-07 | $474.00M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $367.00M 10-Q · filed 2025-11-05 | $514.00M derived: sum of 2 quarters · filed 2026-08-07 | $630.00M 10-Q · filed 2025-11-05 | $287.00M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $147.00M 10-Q · filed 2026-08-07 | $262.00M 10-Q · filed 2026-08-07 | -$80.00M derived: sum of 3 quarters · filed 2026-08-07 | -$122.00M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | -$115.00M 10-Q · filed 2026-05-04 | $115.00M 10-Q · filed 2025-05-02 | -$227.00M derived: sum of 2 quarters · filed 2026-05-04 | -$269.00M derived: sum of 3 quarters · filed 2026-05-04 | -$277.00M derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | -$112.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$154.00M derived: sum of 2 quarters · filed 2026-02-24 | -$162.00M derived: sum of 3 quarters · filed 2026-02-24 | -$30.00M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | -$42.00M 10-Q · filed 2025-11-05 | -$50.00M derived: sum of 2 quarters · filed 2025-11-05 | $82.00M 10-Q · filed 2025-11-05 | $831.00M derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | -$8.00M 10-Q · filed 2025-08-05 | $125.00M 10-Q · filed 2025-08-05 | $873.00M derived: sum of 3 quarters · filed 2025-08-05 | $812.00M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-03-31 | $143.00M 10-Q · filed 2025-05-02 | $881.00M derived: sum of 2 quarters · filed 2025-05-02 | $820.00M derived: sum of 3 quarters · filed 2025-05-02 | $749.00M derived: sum of 4 quarters · filed 2025-05-02 | ||
| 2023-12-31 | $738.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $677.00M derived: sum of 2 quarters · filed 2025-02-25 | $606.00M derived: sum of 3 quarters · filed 2025-02-25 | $411.00M 10-K · filed 2025-02-25 | ||
| 2023-09-30 | -$61.00M 10-Q · filed 2024-11-06 | $61.00M 10-Q · filed 2023-11-03 | -$132.00M derived: sum of 2 quarters · filed 2024-11-06 | -$327.00M 10-Q · filed 2024-11-06 | $327.00M 10-Q · filed 2023-11-03 | $159.00M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$71.00M 10-Q · filed 2024-08-05 | $267.00M 10-Q · filed 2024-08-05 | $220.00M derived: sum of 3 quarters · filed 2024-08-05 | -$1.00M derived: sum of 4 quarters · filed 2024-08-05 | ||
| 2023-03-31 | $338.00M 10-Q · filed 2024-05-03 | $291.00M derived: sum of 2 quarters · filed 2024-05-03 | $70.00M derived: sum of 3 quarters · filed 2024-05-03 | $95.00M derived: sum of 4 quarters · filed 2024-05-03 | ||
| 2022-12-31 | -$47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$268.00M derived: sum of 2 quarters · filed 2024-02-26 | -$243.00M derived: sum of 3 quarters · filed 2024-02-26 | -$462.00M 10-K · filed 2024-02-26 | ||
| 2022-09-30 | -$221.00M 10-Q · filed 2023-11-03 | -$196.00M derived: sum of 2 quarters · filed 2023-11-03 | -$415.00M 10-Q · filed 2023-11-03 | -$544.00M derived: sum of 4 quarters · filed 2023-11-03 | ||
| 2022-06-30 | $25.00M 10-Q · filed 2023-08-07 | -$194.00M 10-Q · filed 2023-08-07 | -$323.00M derived: sum of 3 quarters · filed 2023-08-07 | -$233.00M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-03-31 | -$225.00M 10-Q · filed 2023-05-05 | -$348.00M derived: sum of 2 quarters · filed 2023-05-05 | -$258.00M derived: sum of 3 quarters · filed 2023-05-05 | -$276.00M derived: sum of 4 quarters · filed 2023-05-05 | ||
| 2021-12-31 | -$123.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | -$33.00M derived: sum of 2 quarters · filed 2023-02-24 | -$51.00M derived: sum of 3 quarters · filed 2023-02-24 | -$232.00M 10-K · filed 2023-02-24 | ||
| 2021-09-30 | $90.00M 10-Q · filed 2022-11-03 | $72.00M derived: sum of 2 quarters · filed 2022-11-03 | -$109.00M 10-Q · filed 2022-11-03 | -$458.00M derived: sum of 4 quarters · filed 2022-11-03 | ||
| 2021-06-30 | -$18.00M 10-Q · filed 2022-08-05 | -$199.00M 10-Q · filed 2022-08-05 | -$548.00M derived: sum of 3 quarters · filed 2022-08-05 | -$505.00M derived: sum of 4 quarters · filed 2022-08-05 | ||
| 2021-03-31 | -$181.00M 10-Q · filed 2022-05-05 | -$530.00M derived: sum of 2 quarters · filed 2022-05-05 | -$487.00M derived: sum of 3 quarters · filed 2022-05-05 | -$23.00M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2020-12-31 | -$349.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$306.00M derived: sum of 2 quarters · filed 2022-02-25 | $158.00M derived: sum of 3 quarters · filed 2022-02-25 | $163.00M 10-K · filed 2022-02-25 | ||
| 2020-09-30 | $43.00M 10-Q · filed 2021-11-05 | $507.00M derived: sum of 2 quarters · filed 2021-11-05 | $512.00M 10-Q · filed 2021-11-05 | $622.00M derived: sum of 4 quarters · filed 2021-11-05 | ||
| 2020-06-30 | $464.00M 10-Q · filed 2021-08-09 | $469.00M 10-Q · filed 2021-08-09 | $579.00M derived: sum of 3 quarters · filed 2021-08-09 | $554.00M derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | -$4.00M 10-Q · filed 2021-05-05 | $115.00M derived: sum of 2 quarters · filed 2021-05-05 | $90.00M derived: sum of 3 quarters · filed 2021-05-05 | $51.00M derived: sum of 4 quarters · filed 2021-05-05 | ||
| 2019-12-31 | $119.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $94.00M derived: sum of 2 quarters · filed 2021-02-25 | $55.00M derived: sum of 3 quarters · filed 2021-02-25 | $160.00M 10-K · filed 2021-02-25 | ||
| 2019-09-30 | -$25.00M 10-Q · filed 2020-11-05 | -$64.00M derived: sum of 2 quarters · filed 2020-11-05 | $41.00M 10-Q · filed 2020-11-05 | -$45.00M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-30 | -$39.00M 10-Q · filed 2020-08-05 | $75.00M 10-Q · filed 2020-08-05 | -$20.00M derived: sum of 3 quarters · filed 2020-08-05 | -$10.00M derived: sum of 4 quarters · filed 2020-08-05 | ||
| 2019-03-31 | $114.00M 10-Q · filed 2020-05-06 | $19.00M derived: sum of 2 quarters · filed 2020-05-06 | $29.00M derived: sum of 3 quarters · filed 2020-05-06 | |||
| 2018-12-31 | -$95.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$85.00M derived: sum of 2 quarters · filed 2020-02-26 | -$35.00M 10-K · filed 2020-02-26 | |||
| 2018-09-30 | $10.00M 10-Q · filed 2019-11-05 | $60.00M 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |